Showing results (201-210 of 279) with videos related to
Sort By:
Pageof 28
Haematologica|January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Chronic myelogenous leukemia, version 1.2015Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasmsBrady L Stein, Jason Gotlib, Murat Arcasoy, et al.The New England Journal of Medicine|March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.Theranostics|September 15, 2020
Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine conceptsPeter Valent, Cem Akin, Karin Hartmann, et al.The Journal of Allergy and Clinical Immunology|June 21, 2020
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinionsPeter Valent, Cem Akin, Patrizia Bonadonna, et al.Nature Medicine|December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trialJason Gotlib, Andreas Reiter, Deepti H Radia, et al.The Journal of Allergy and Clinical Immunology. in Practice|March 28, 2022
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical PracticePeter Valent, Karin Hartmann, Juliana Schwaab, et al.Pageof 28